Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A.

BMC Cancer. 2019 Apr 3;19(1):304. doi: 10.1186/s12885-019-5528-1.

2.

Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer.

Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, Hendlisz A, Flamen P.

J Nucl Med. 2019 Oct;60(10):1366-1372. doi: 10.2967/jnumed.118.222919. Epub 2019 Mar 8.

PMID:
30850494
3.

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A.

BMC Cancer. 2019 Feb 12;19(1):134. doi: 10.1186/s12885-019-5319-8.

4.

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A.

Oncotarget. 2018 Apr 3;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 3.

5.

Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.

Van Roy N, Van Der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K.

Clin Cancer Res. 2017 Oct 15;23(20):6305-6314. doi: 10.1158/1078-0432.CCR-17-0675. Epub 2017 Jul 14.

6.

Tackling immunomonitoring in gastrointestinal cancer.

Anciaux M, Vandeputte C, Hendlisz A.

Curr Opin Oncol. 2017 Jul;29(4):296-305. doi: 10.1097/CCO.0000000000000383. Review.

PMID:
28505010
7.

Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates.

Ory D, Celen S, Gijsbers R, Van Den Haute C, Postnov A, Koole M, Vandeputte C, Andrés JI, Alcazar J, De Angelis M, Langlois X, Bhattacharya A, Schmidt M, Letavic MA, Vanduffel W, Van Laere K, Verbruggen A, Debyser Z, Bormans G.

J Nucl Med. 2016 Sep;57(9):1436-41. doi: 10.2967/jnumed.115.169995. Epub 2016 May 19.

8.

Erratum: preoperative chemosensitivity testing as predictor of treatment benefit in adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, El Mansy H, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Van den Eynde M, Maréchal R, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart M, Van Laethem JL, Flamen P.

BMC Cancer. 2015 Mar 25;15:173. doi: 10.1186/s12885-015-1181-5. No abstract available.

9.

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Hendlisz A, Deleporte A, Vandeputte C, Charette N, Paesmans M, Guiot T, Garcia C, Flamen P.

BMJ Open. 2015 Mar 9;5(3):e007189. doi: 10.1136/bmjopen-2014-007189.

10.

Streptococcal pharyngitis in children: to treat or not to treat?

Van Brusselen D, Vlieghe E, Schelstraete P, De Meulder F, Vandeputte C, Garmyn K, Laffut W, Van de Voorde P.

Eur J Pediatr. 2014 Oct;173(10):1275-83. doi: 10.1007/s00431-014-2395-2. Epub 2014 Aug 12. Review.

PMID:
25113742
11.

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, Hendlisz A.

BMC Cancer. 2014 May 30;14:385. doi: 10.1186/1471-2407-14-385.

12.

Bioluminescence imaging of stroke-induced endogenous neural stem cell response.

Vandeputte C, Reumers V, Aelvoet SA, Thiry I, De Swaef S, Van den Haute C, Pascual-Brazo J, Farr TD, Vande Velde G, Hoehn M, Himmelreich U, Van Laere K, Debyser Z, Gijsbers R, Baekelandt V.

Neurobiol Dis. 2014 Sep;69:144-55. doi: 10.1016/j.nbd.2014.05.014. Epub 2014 May 27.

PMID:
24878507
13.

Ras in digestive oncology: from molecular biology to clinical implications.

Charette N, Vandeputte C, Stärkel P.

Curr Opin Oncol. 2014 Jul;26(4):454-61. doi: 10.1097/CCO.0000000000000088. Review.

PMID:
24849046
14.

In times of crisis, go liquid!

Hendlisz A, Deleporte A, Vandeputte C.

Curr Opin Oncol. 2014 Jul;26(4):440. doi: 10.1097/CCO.0000000000000084. No abstract available.

PMID:
24840524
15.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.

Hendlisz A, Golfinopoulos V, Deleporte A, Paesmans M, Mansy HE, Garcia C, Peeters M, Annemans L, Vandeputte C, Maetens M, Borbath I, Dresse D, Houbiers G, Fried M, Awada A, Piccart M, Laethem JL, Flamen P.

BMC Cancer. 2013 Apr 12;13:190. doi: 10.1186/1471-2407-13-190. Erratum in: BMC Cancer. 2015;15:173.

16.

In vitro and in vivo comparison of 18F and 123I-labeled ML10 with 68Ga-Cys2-AnxA5 for molecular imaging of apoptosis.

Bauwens M, De Saint-Hubert M, Cleynhens J, Vandeputte C, Li J, Devos E.

Q J Nucl Med Mol Imaging. 2013 Jun;57(2):187-200. Epub 2013 Feb 6.

PMID:
23389693
17.

Mapping of oxygen by imaging lipids relaxation enhancement: a potential sensitive endogenous MRI contrast to map variations in tissue oxygenation.

Jordan BF, Magat J, Colliez F, Ozel E, Fruytier AC, Marchand V, Mignion L, Bouzin C, Cani PD, Vandeputte C, Feron O, Delzenne N, Himmelreich U, Denolin V, Duprez T, Gallez B.

Magn Reson Med. 2013 Sep;70(3):732-44. doi: 10.1002/mrm.24511. Epub 2012 Sep 28.

18.

Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model.

Vandeputte C, Casteels C, Struys T, Koole M, van Veghel D, Evens N, Gerits A, Dresselaers T, Lambrichts I, Himmelreich U, Bormans G, Van Laere K.

Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1796-806. doi: 10.1007/s00259-012-2209-6. Epub 2012 Aug 16.

PMID:
22895861
19.

Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer.

Evens N, Vandeputte C, Coolen C, Janssen P, Sciot R, Baekelandt V, Verbruggen AM, Debyser Z, Van Laere K, Bormans GM.

Nucl Med Biol. 2012 Apr;39(3):389-99. doi: 10.1016/j.nucmedbio.2011.09.005. Epub 2011 Dec 11.

PMID:
22154685
20.

Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging.

Evens N, Vandeputte C, Muccioli GG, Lambert DM, Baekelandt V, Verbruggen AM, Debyser Z, Van Laere K, Bormans GM.

Bioorg Med Chem. 2011 Aug 1;19(15):4499-505. doi: 10.1016/j.bmc.2011.06.033. Epub 2011 Jun 16.

PMID:
21737287
21.

A PET brain reporter gene system based on type 2 cannabinoid receptors.

Vandeputte C, Evens N, Toelen J, Deroose CM, Bosier B, Ibrahimi A, Van der Perren A, Gijsbers R, Janssen P, Lambert DM, Verbruggen A, Debyser Z, Bormans G, Baekelandt V, Van Laere K.

J Nucl Med. 2011 Jul;52(7):1102-9. doi: 10.2967/jnumed.110.084426. Epub 2011 Jun 16.

22.

Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.

Casteels C, Vandeputte C, Rangarajan JR, Dresselaers T, Riess O, Bormans G, Maes F, Himmelreich U, Nguyen H, Van Laere K.

Exp Neurol. 2011 Jun;229(2):440-9. doi: 10.1016/j.expneurol.2011.03.014. Epub 2011 Mar 31.

PMID:
21459091
23.

[About an extreme case of giant lymphoedema of the upper limb: ligasure may be useful and a multidisciplinary approach is mandatory].

Lafosse A, Vandeputte C, Sabor I, Mahaudens P, Denoel C.

Ann Chir Plast Esthet. 2011 Aug;56(4):325-8. doi: 10.1016/j.anplas.2010.10.011. Epub 2011 Jan 14. French.

PMID:
21237550
24.

Characterization of the inflammatory response in a photothrombotic stroke model by MRI: implications for stem cell transplantation.

Vandeputte C, Thomas D, Dresselaers T, Crabbe A, Verfaillie C, Baekelandt V, Van Laere K, Himmelreich U.

Mol Imaging Biol. 2011 Aug;13(4):663-71. doi: 10.1007/s11307-010-0395-9.

PMID:
20700767
25.

Automated quantitative gait analysis in animal models of movement disorders.

Vandeputte C, Taymans JM, Casteels C, Coun F, Ni Y, Van Laere K, Baekelandt V.

BMC Neurosci. 2010 Aug 9;11:92. doi: 10.1186/1471-2202-11-92.

26.

Effects of MRI contrast agents on the stem cell phenotype.

Crabbe A, Vandeputte C, Dresselaers T, Sacido AA, Verdugo JM, Eyckmans J, Luyten FP, Van Laere K, Verfaillie CM, Himmelreich U.

Cell Transplant. 2010;19(8):919-36. doi: 10.3727/096368910X494623. Epub 2010 Mar 26.

PMID:
20350351
27.

Highly efficient multicistronic lentiviral vectors with peptide 2A sequences.

Ibrahimi A, Vande Velde G, Reumers V, Toelen J, Thiry I, Vandeputte C, Vets S, Deroose C, Bormans G, Baekelandt V, Debyser Z, Gijsbers R.

Hum Gene Ther. 2009 Aug;20(8):845-60. doi: 10.1089/hum.2008.188.

PMID:
19419274
28.

Washing toys in a neonatal intensive care unit decreases bacterial load of potential pathogens.

Naesens R, Jeurissen A, Vandeputte C, Cossey V, Schuermans A.

J Hosp Infect. 2009 Feb;71(2):197-8. doi: 10.1016/j.jhin.2008.10.018. Epub 2008 Dec 18. No abstract available.

PMID:
19100660
29.

Actions of R- and S-verapamil and nifedipine on rat vascular and intestinal smooth muscle.

Cleary L, Vandeputte C, Kelly JG, Docherty JR.

Auton Autacoid Pharmacol. 2004 Jul;24(3):63-7.

PMID:
15541013
30.

Deletion of inducible nitric oxide synthase decreases mesenteric vascular responsiveness in portal hypertensive mice.

Bexis S, Vandeputte C, McCormick PA, Docherty JR.

Eur J Pharmacol. 2004 Sep 24;499(3):325-33.

PMID:
15381055
32.
33.

Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)-adrenoceptor knockout mice.

Vandeputte C, Docherty JR.

Eur J Pharmacol. 2002 Dec 13;457(1):45-9.

PMID:
12460642
34.

Internal and external validation of the NOSEP prediction score for nosocomial sepsis in neonates.

Mahieu LM, De Dooy JJ, Cossey VR, Goossens LL, Vrancken SL, Jespers AY, Vandeputte CT, De Muynck AO.

Crit Care Med. 2002 Jul;30(7):1459-66.

PMID:
12130962
35.

Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice.

Cleary L, Vandeputte C, Docherty JR.

Br J Pharmacol. 2002 Jul;136(6):857-64.

36.
37.

Lack of involvement of pertussis toxin-sensitive G-proteins in norepinephrine-induced vasoconstriction of rat aorta smooth muscle.

Petitcolin MA, Vandeputte C, Spitzbarth-Régrigny E, Bueb JL, Capdeville-Atkinson C, Tschirhart E.

Biochem Pharmacol. 2001 Feb 15;61(4):485-91.

PMID:
11226383
38.

Melatonin potentiates NE-induced vasoconstriction without augmenting cytosolic calcium concentration.

Vandeputte C, Giummelly P, Atkinson J, Delagrange P, Scalbert E, Capdeville-Atkinson C.

Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H420-5.

39.

A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol.

Vandeputte C, Guizon I, Genestie-Denis I, Vannier B, Lorenzon G.

Cell Biol Toxicol. 1994 Dec;10(5-6):415-21.

PMID:
7697505
40.

Treatment for the chemically dependent.

Vandeputte C.

Provider. 1988 Aug;14(8):26, 28. No abstract available.

PMID:
10318095

Supplemental Content

Loading ...
Support Center